Formula Growth Ltd. trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 88.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,810 shares of the medical equipment provider's stock after selling 38,000 shares during the period. Formula Growth Ltd.'s holdings in Hologic were worth $347,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Forum Financial Management LP bought a new stake in shares of Hologic during the fourth quarter valued at approximately $324,000. Commerce Bank increased its holdings in Hologic by 2.5% in the 4th quarter. Commerce Bank now owns 12,243 shares of the medical equipment provider's stock valued at $883,000 after buying an additional 294 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in Hologic by 4.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 276,408 shares of the medical equipment provider's stock valued at $19,912,000 after buying an additional 12,695 shares during the period. Champlain Investment Partners LLC acquired a new position in shares of Hologic in the 4th quarter valued at $79,291,000. Finally, Insigneo Advisory Services LLC lifted its holdings in shares of Hologic by 8.1% during the 4th quarter. Insigneo Advisory Services LLC now owns 6,061 shares of the medical equipment provider's stock worth $437,000 after acquiring an additional 454 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on HOLX shares. Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a research note on Monday, February 3rd. Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada cut their price objective on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Finally, Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic has an average rating of "Hold" and an average price target of $84.62.
View Our Latest Analysis on Hologic
Hologic Stock Performance
HOLX traded up $0.09 during trading hours on Thursday, reaching $58.24. The company's stock had a trading volume of 1,223,463 shares, compared to its average volume of 1,955,799. The firm has a market cap of $13.07 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52 week low of $55.89 and a 52 week high of $84.67. The company's 50-day moving average is $61.24 and its 200-day moving average is $70.37.
Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.
About Hologic
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Further Reading
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
